open access

Vol 6, No 1 (2001)
Untitled
Published online: 2001-01-01
Submitted:
Get Citation

14. Search for improvement of the therapeutic ratio in radiotherapy for non-small cell lung cancer (NSCLC)

L. Kępka, J. Fijuth, A. Żółciak, D. Blatkiewicz, A. Ciarcińska, W. Bulski
DOI: 10.1016/S1507-1367(01)70384-7
·
Rep Pract Oncol Radiother 2001;6(1):33.

open access

Vol 6, No 1 (2001)
Untitled
Published online: 2001-01-01
Submitted:

Abstract

There are several approaches under investigation in view of improvement of the therapeutic ratio of NSCLC radiotherapy in our Department:

1/ Dose escalation above 70 Gy using conformal radiotherapy techniques, 2/ accelerated radiotherapy with or without induction chemotherapy addressed to III stage tumours, 3/ conformal postoperative radiotherapy to total minimum dose in PTV of 50 Gy addressed to completely resected III stage tumours.

Ad 1/ From XI 1998 to XI 2000 43 patients were included in dose escalation study. Doses from 70 to 74 Gy were delivered. Apart from one toxic death, due to radiation pneumonitis, toxicity was acceptable. Since 1999 for NO patients the study of omission of elective irradiation is conducted. By the time being 10 patients were irradiated with omission of elective fields. There was no relapse in non-treated “elective areas”. The actuarial 1-, 2- and 3-year survival were respectively 84-, 64-, and 42%. There were 14 local relapses in 19 progressions observed in the entire group. In spite of encouraging results a high level of local relapses shows the limits of moderate dose escalation using conformal techniques and conventional fractionation in improvement of local control of NSCLC.

Ad 2/ From III 1999 two different accelerated radiation therapy schedules are investigated for III stage tumours. Forty patients were enrolled in the study: 26 were irradiated according to accelerated hyperfractionated radiotherapy (57 Gy in 40 fractions [first week: elective fields −1.2 Gy × 2 per day, 3 remaining weeks 1.8 Gy to elective fields and 1.2 Gy boost to tumour] during 26 days), 14 were irradiated according to accelerated conformal radiotherapy with concurrent boost (56.7 Gy in 21 fractions and 26 days: all treatment was conformally planned and delivered: 1,9 Gy per fraction to the limited elective field and 0.8 Gy as a concurrent boost to the GTV). There was no difference on compliance with treatment plan, toxicity and response rate (80- and 72%) in the both investigated groups.

Ad 3/ From I 1999 eleven patients were enrolled in the phase II study of postoperative conformal radiotherapy of the region of the highest probability of microscopic invasion by the disease to the minimum dose of 50 Gy in PTV. The study is conducted in view of the future design of randomised study addressing question of the value of postoperative radiotherapy using modern techniques in management of NSCLC.

Abstract

There are several approaches under investigation in view of improvement of the therapeutic ratio of NSCLC radiotherapy in our Department:

1/ Dose escalation above 70 Gy using conformal radiotherapy techniques, 2/ accelerated radiotherapy with or without induction chemotherapy addressed to III stage tumours, 3/ conformal postoperative radiotherapy to total minimum dose in PTV of 50 Gy addressed to completely resected III stage tumours.

Ad 1/ From XI 1998 to XI 2000 43 patients were included in dose escalation study. Doses from 70 to 74 Gy were delivered. Apart from one toxic death, due to radiation pneumonitis, toxicity was acceptable. Since 1999 for NO patients the study of omission of elective irradiation is conducted. By the time being 10 patients were irradiated with omission of elective fields. There was no relapse in non-treated “elective areas”. The actuarial 1-, 2- and 3-year survival were respectively 84-, 64-, and 42%. There were 14 local relapses in 19 progressions observed in the entire group. In spite of encouraging results a high level of local relapses shows the limits of moderate dose escalation using conformal techniques and conventional fractionation in improvement of local control of NSCLC.

Ad 2/ From III 1999 two different accelerated radiation therapy schedules are investigated for III stage tumours. Forty patients were enrolled in the study: 26 were irradiated according to accelerated hyperfractionated radiotherapy (57 Gy in 40 fractions [first week: elective fields −1.2 Gy × 2 per day, 3 remaining weeks 1.8 Gy to elective fields and 1.2 Gy boost to tumour] during 26 days), 14 were irradiated according to accelerated conformal radiotherapy with concurrent boost (56.7 Gy in 21 fractions and 26 days: all treatment was conformally planned and delivered: 1,9 Gy per fraction to the limited elective field and 0.8 Gy as a concurrent boost to the GTV). There was no difference on compliance with treatment plan, toxicity and response rate (80- and 72%) in the both investigated groups.

Ad 3/ From I 1999 eleven patients were enrolled in the phase II study of postoperative conformal radiotherapy of the region of the highest probability of microscopic invasion by the disease to the minimum dose of 50 Gy in PTV. The study is conducted in view of the future design of randomised study addressing question of the value of postoperative radiotherapy using modern techniques in management of NSCLC.

Get Citation
About this article
Title

14. Search for improvement of the therapeutic ratio in radiotherapy for non-small cell lung cancer (NSCLC)

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 6, No 1 (2001)

Pages

33

Published online

2001-01-01

DOI

10.1016/S1507-1367(01)70384-7

Bibliographic record

Rep Pract Oncol Radiother 2001;6(1):33.

Authors

L. Kępka
J. Fijuth
A. Żółciak
D. Blatkiewicz
A. Ciarcińska
W. Bulski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl